Back to Results
First PageMeta Content
Neurotrauma / Medical emergencies / Benzothiazoles / Riluzole / Spinal cord injury / Amyotrophic lateral sclerosis / Motor neurone disease / Olesoxime / Medicine / Health / Rare diseases


J Neurosurg Spine (Suppl) 17:151–156, 2012 Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial Michael G. Fehlings, M.D., Ph.D.,1 Jefferson R.
Add to Reading List

Document Date: 2014-11-06 15:33:24

Open Document

File Size: 1.005,38 KB

Share Result on Facebook

City

Houston / Charlottesville / Baltimore / Toronto / Lyon / Chicago / /

Company

Biomet / NuVasive / Medtronic / Wilson / /

Country

Japan / Canada / Singapore / /

Currency

pence / /

/

Event

FDA Phase / /

Facility

University of Virginia Health System / Pharmacy Adverse Events / University of Miami / Toronto Western Hospital / University of Texas Health Science Center / University of Louisville / Methodist Hospital / University of Kentucky / University of Houston College / University of Toronto / University of Maryland / Thomas Jefferson University / University of Texas Health Sciences Center / University of Texas School / /

IndustryTerm

treatment of the neurodegenerative disorder / study protocol / pharmaceutical agents / collaborative network / food / /

MedicalCondition

DF / acute traumatic spinal cord injury / acidosis / acute spinal cord trauma / Novel injury / ALS / neuron disease / amyotrophic lateral sclerosis / severe traumatic brain injury / injury / kidney disease injuries / heimer disease / spinal cord trauma / primary spinal cord trauma / deep vein thrombosis/pulmonary embolus / infections / experimental contusive spinal cord injury / Sygen multicenter acute spinal cord injury / Spinal Cord Injury / MND / specific injury / schizophrenia / acute spinal-cord injury / Parkinson disease / experimental spinal cord injury / mental disorder / pain / secondary injury / acute spinal cord injury / human spinal cord injury / neurological tissue injury / excitotoxicity-mediated secondary injury / traumatic spinal cord injury / injuries / Cure Paralysis / /

MedicalTreatment

antibiotics / Neurosurgery / Neurological Surgery / /

Organization

Human Protection Office / University of Texas Health Sciences Center / University of Maryland / University of Texas Health Science Center / AOSpine / University of Houston College of Pharmacy Adverse Events / Division of Neurosurgery / University of Miami / Injury Association / University of Louisville / Society of Paraplegia / Dana Reeve Foundation / Division of Spinal Disorders / NACTN / Department of Neurosurgery / American Spinal Injury Association / US Army Medical Research and Materiel Command office of Research Protections / Miami Project / Methodist Hospital / Thomas Jefferson University / Philadelphia / University of Virginia Health System / FDA / Toronto Western Hospital / Krembil Neuroscience Center / Department of Defense / of Texas Health Sciences Center / Department of Surgery / University of Texas School of Public Health / University of Toronto / International Spinal Cord Society / University of Kentucky / Louisville / /

Person

Tator / Shaffrey / Robert G. Grossman / Neurosurg Spine (Suppl) / Ann Acad Med / Michael G. Fehlings / /

Position

investigator / study coordinator / consultant / Author / cipal investigator / /

Product

methylprednisolone / Riluzole / omeprazole / naloxone / phenytoin / Impact / lidocaine / NCT00876889 / /

ProvinceOrState

Texas / Kentucky / Virginia / Maryland / Pennsylvania / Manitoba / Florida / Ontario / /

Technology

Neuroscience / study protocol / Neurosurgery / /

URL

http /

SocialTag